ArticleJournal of neurology2026
Ocrelizumab-related organizing pneumonia in multiple sclerosis: insights from a case series and literature review.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrganizing pneumonia (OP) is a rare interstitial lung disease that may occur secondary to drug exposure. Although OP has been described during rituximab treatment, the association with ocrelizumab remains elusive, with evidence limited to a few recent cases. We aimed to characterize ocrelizumab-related OP in the context of the existing literature.
methodsClinical, radiological, laboratory, therapeutic, and outcome data were retrospectively collected from multiple sclerosis (MS) patients with ocrelizumab-associated OP at our center and descriptively compared with 17 cases identified through a literature review.
resultsAmong 626 ocrelizumab-treated MS patients, five cases of OP were observed (0.8%) (3 females, median age=54 years, range=27-64). OP developed after a mean treatment exposure of 5.1 years (standard deviation (SD=2.9) and a mean interval of 10.8 weeks (SD=10.4) following the last infusion. Clinical presentation was characterized by persistent antibiotic-refractory fever, sometimes accompanied by nonproductive cough. Chest CT consistently showed patchy ground-glass opacities and consolidations. All patients received prednisone 0.5-1 mg/kg/day for a median duration of 30 days (range=15-60), followed by gradual tapering. Despite initial clinical response, respiratory relapses and residual radiological lung abnormalities were observed in four patients during a median follow-up of 29 months (range=4-47). Ocrelizumab was discontinued in all patients. Only one patient initiated ozanimod two years after OP onset. DISCUSSION: Our findings support the emerging evidence of ocrelizumab-related OP and show substantial consistency with previously reported cases. Further studies are needed to clarify the potential role of CD20+ lymphocyte depletion in OP pathogenesis.
Indexed as
Identifiers
42749938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.